Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Inozyme reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Inozyme announced earnings per share of $-0.38 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.44 on revenue of $0.00.
Inozyme 's are down 4.96% and is trading at $1.70 , still down 83.87% from its 52 week high of $10.54 set on Wednesday, November 17, 2021.
Inozyme shares gained 4.94% to trade at $1.70 in intra-day trade the report.
Inozyme follows other major Healthcare sector earnings this month
Inozyme's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar